Last updated: September 2, 2026
Dapagliflozin has evolved from a type 2 diabetes drug into a multi-indication cardiovascular and renal product. AstraZeneca’s Farxiga and Forxiga franchises have expanded through heart-failure and chronic-kidney-disease approvals, offsetting the erosion of the original diabetes market. Reported global sales increased from roughly $2 billion in 2020 to more than $5 billion in 2023, making dapagliflozin one of AstraZeneca’s largest growth products.[1]
The commercial outlook depends on four factors: continued use across heart failure and chronic kidney disease, competition from empagliflozin and GLP-1 medicines, U.S. generic timing, and AstraZeneca’s ability to protect price through indication-specific evidence and market access.
What is dapagliflozin and how is it used?
Dapagliflozin is an oral sodium-glucose cotransporter-2, or SGLT2, inhibitor. It reduces renal glucose reabsorption and increases urinary glucose excretion. The drug is marketed primarily as Farxiga in the United States and Forxiga in many international markets.
| Attribute |
Dapagliflozin |
| Active ingredient |
Dapagliflozin propanediol |
| Drug class |
SGLT2 inhibitor |
| Originator |
AstraZeneca, originally developed with Bristol-Myers Squibb |
| U.S. brand |
Farxiga |
| International brand |
Forxiga |
| Initial U.S. approval |
January 2014 |
| Main dosage form |
Oral tablets |
| Common strengths |
5 mg and 10 mg |
| Core indications |
Type 2 diabetes, heart failure, chronic kidney disease |
| Principal competitors |
Jardiance, Invokana, Steglatro |
| U.S. regulatory pathway |
New drug application, or NDA |
| Biosimilar exposure |
None; dapagliflozin is a small-molecule drug |
The product’s commercial value is no longer tied only to glycemic control. The strongest growth has come from outcome-driven use in patients with heart failure and chronic kidney disease, including some patients without diabetes.
How has dapagliflozin revenue changed over time?
AstraZeneca’s reported Farxiga/Forxiga sales have grown sharply since 2020. The expansion reflects additional indications, wider guideline adoption, increased diagnosis of chronic kidney disease, and use in patients without type 2 diabetes.
| Year |
Approximate global Farxiga/Forxiga sales |
Main growth drivers |
| 2020 |
Approximately $2 billion |
Diabetes base and early heart-failure uptake |
| 2021 |
Approximately $2.8 billion |
Heart-failure approval and broader cardiovascular use |
| 2022 |
Approximately $4.5 billion |
Chronic-kidney-disease adoption and guideline inclusion |
| 2023 |
Approximately $5.8 billion |
Broader cardiorenal use and international expansion |
Reported figures can differ by annual-report presentation, currency conversion, and treatment of collaboration revenue. AstraZeneca identifies Farxiga as a key growth medicine in its cardiovascular, renal and metabolism portfolio.[1]
What is the revenue trajectory for dapagliflozin?
The trajectory has three phases:
- Diabetes-led commercialization, 2014-2019. Dapagliflozin competed mainly against other SGLT2 inhibitors and established diabetes therapies.
- Cardiovascular expansion, 2020-2021. Heart-failure data and regulatory approvals moved the product into cardiology.
- Cardiorenal platform expansion, 2022 onward. Chronic kidney disease created a larger addressable population and reduced dependence on diabetes prescribing.
The shift from diabetes treatment to cardiorenal risk reduction materially increased the product’s revenue ceiling. Heart-failure and chronic-kidney-disease patients are often treated for longer periods than patients receiving glucose-lowering therapy alone, supporting prescription persistence.
Which indications drive the dapagliflozin market?
Heart failure and chronic kidney disease are the principal commercial growth engines.
Type 2 diabetes
Dapagliflozin remains a widely used add-on treatment for adults with type 2 diabetes. Its clinical value includes glucose lowering, modest weight reduction and blood-pressure reduction. Diabetes is the most mature segment and faces the greatest pricing pressure from generic oral medicines and newer incretin therapies.
Heart failure
Dapagliflozin received FDA approval to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart-failure visits in adults with heart failure with reduced ejection fraction. Subsequent evidence supported use across a broader heart-failure population, including patients with preserved or mildly reduced ejection fraction.[2]
Heart-failure use strengthened the product’s position because treatment decisions are increasingly guided by outcome data rather than hemoglobin A1c reduction. SGLT2 inhibitors are now part of guideline-directed medical therapy for many heart-failure patients.
Chronic kidney disease
The FDA approved Farxiga to reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.[3]
This indication expanded the addressable market beyond diabetes. Many chronic-kidney-disease patients do not have diabetes, which makes renal screening and nephrology referral central to future demand.
Pediatric diabetes
FDA labeling has expanded to include pediatric patients in defined type 2 diabetes settings. Pediatric use is commercially smaller than adult cardiorenal indications but can extend clinical adoption and provide limited regulatory exclusivity in certain circumstances.[4]
How does dapagliflozin compare with empagliflozin and other SGLT2 inhibitors?
Dapagliflozin and empagliflozin are the leading global SGLT2 competitors. Their commercial competition is based on clinical evidence, guideline placement, formulary status, contracting and physician familiarity.
| Product |
Active ingredient |
Originator |
Principal strengths |
| Farxiga/Forxiga |
Dapagliflozin |
AstraZeneca |
Heart failure, chronic kidney disease, diabetes |
| Jardiance |
Empagliflozin |
Boehringer Ingelheim/Eli Lilly |
Cardiovascular outcomes, heart failure, diabetes, kidney evidence |
| Invokana |
Canagliflozin |
Johnson & Johnson, later commercialized by subsidiaries and partners |
Diabetes and kidney outcomes |
| Steglatro |
Ertugliflozin |
Merck/MSD and Pfizer |
Diabetes, less extensive cardiorenal commercial position |
Jardiance has a strong cardiovascular franchise and substantial formulary presence. Farxiga’s competitive position is strongest where physicians prioritize chronic kidney disease and heart-failure outcomes. The products are clinically differentiated less by mechanism than by trial populations, labeling, evidence breadth and payer access.
GLP-1 receptor agonists, including semaglutide and tirzepatide, are indirect competitors. They compete for diabetes spending, obesity management and cardiometabolic treatment budgets. They do not fully replace SGLT2 inhibitors in heart failure or chronic-kidney-disease treatment, but they can reduce the share of diabetes prescriptions available to dapagliflozin.
What is the FDA regulatory status of Farxiga?
Farxiga is an FDA-approved prescription drug with indications spanning diabetes, heart failure and chronic kidney disease. The FDA label contains warnings and precautions relating to ketoacidosis, volume depletion, renal function, genital infections and necrotizing fasciitis of the perineum.[4]
The product’s regulatory expansion is commercially important because each major indication creates a distinct prescriber base:
- Endocrinologists and primary-care physicians for type 2 diabetes.
- Cardiologists for heart failure.
- Nephrologists and primary-care physicians for chronic kidney disease.
- Hospital systems for discharge and transition-of-care protocols.
The broad label supports cross-specialty detailing and reduces reliance on a single therapeutic market.
What patents protect dapagliflozin?
Dapagliflozin is protected by a layered patent estate that includes the active compound, formulations, crystalline forms and methods of treatment. The foundational U.S. compound patent, commonly associated with U.S. Patent No. 6,515,117, reached its ordinary expiration period around 2020, subject to patent-term adjustment and pediatric exclusivity considerations.[5]
What are the principal dapagliflozin patent categories?
| Patent category |
Commercial purpose |
Expected impact |
| Compound patents |
Protect dapagliflozin itself |
Core exclusivity; generally earliest expiration |
| Salt, solvate and crystalline-form patents |
Protect the marketed pharmaceutical form |
Can delay or complicate generic substitution |
| Tablet and formulation patents |
Protect dosage-form composition and manufacturing |
Supports Orange Book litigation |
| Method-of-use patents |
Protect treatment of diabetes, heart failure or kidney disease |
May limit labeled generic uses |
| Combination patents |
Protect use with other active ingredients |
Relevant to combination products |
| Manufacturing patents |
Protect processes and intermediates |
Can raise technical barriers but may not block all generic entry |
The commercial effect of later patents depends on whether they are listed in the FDA Orange Book, whether a generic applicant challenges them, and whether the patented subject matter is necessary for the generic product’s proposed label.
What is the Orange Book status of dapagliflozin?
The FDA Orange Book lists patents associated with Farxiga. Orange Book-listed patents can trigger a statutory stay of approval when the originator files a timely patent-infringement action after receiving a Paragraph IV notice.[6]
The presence of listed patents does not guarantee market exclusivity until every listed patent expires. Generic applicants can:
- Certify that a patent is invalid or will not be infringed.
- Carve out patented methods from the proposed label.
- Challenge formulation or crystalline-form patents.
- Seek a settlement with the originator.
- Delay launch until the relevant patents expire.
Because Orange Book listings and expiration dates can change through regulatory updates, the live FDA listing is the controlling source for product-specific analysis.
When does dapagliflozin lose exclusivity?
Dapagliflozin has already lost or is losing its earliest compound-level exclusivity in several jurisdictions. U.S. generic entry risk is governed by the remaining listed patents, litigation outcomes and any settlement dates, rather than by the original compound patent alone.
U.S. exclusivity timeline
| Milestone |
Date or period |
Commercial significance |
| First U.S. approval |
January 2014 |
Began NCE exclusivity and patent-linked commercial life |
| Core compound patent period |
Around 2020 |
Original compound protection reached expiration period |
| Pediatric exclusivity |
Six-month extension where applicable |
Extended certain regulatory protections |
| Later formulation and method patents |
Varies by patent |
Potentially delays unrestricted generic substitution |
| Generic entry |
Patent- and settlement-dependent |
Could begin with limited or authorized launches before full competition |
The key distinction is between regulatory exclusivity, patent exclusivity and commercial protection from clinical differentiation. These periods do not end on the same date.
Which companies are challenging dapagliflozin patents?
Generic manufacturers have pursued or may pursue ANDA filings for dapagliflozin tablets. Patent challenges typically come from large Indian and U.S.-focused generic companies, including manufacturers with established diabetes portfolios.
The relevant litigation issues include:
- Whether later patents validly cover the marketed tablet.
- Whether a generic’s proposed product infringes crystalline-form or formulation claims.
- Whether method-of-use claims can be avoided through a label carve-out.
- Whether the generic applicant has a first-to-file position.
- Whether the parties agree to an authorized or licensed launch date.
The business impact depends less on the number of defendants than on the earliest applicant capable of securing FDA approval and commercial supply.
What generic entry risks exist for Farxiga?
Generic entry is likely to be staged rather than uniform. Three scenarios are commercially relevant.
Scenario 1: Delayed full generic entry
AstraZeneca maintains enforceable formulation or method patents through litigation or settlement. Generic launches remain blocked until a negotiated date. This preserves a substantial portion of brand revenue but does not eliminate international price pressure.
Scenario 2: Limited or licensed entry
One or more generic companies launch under a settlement, license or authorized-generic arrangement. Price erosion is moderate at first, but pharmacy substitution and payer contracting gradually reduce branded volume.
Scenario 3: Unrestricted multi-source entry
Several ANDA holders launch after the relevant patents are invalidated, expire or are bypassed through label carve-outs. U.S. net sales decline rapidly, often through both unit loss and price compression.
Cardiorenal indications may slow erosion if generic labels do not fully replicate the brand’s patented uses. That protection is strongest when the relevant indication is covered by valid, listed method-of-use claims and physicians prescribe the branded drug specifically for that indication.
How strong is the dapagliflozin patent estate?
The estate is commercially meaningful but weaker than a new chemical entity estate because the foundational compound patent has expired or reached the end of its primary term. Its residual strength depends on later patents and the ability to enforce them against simple tablet copies.
Strengths
- Broad clinical label across diabetes, heart failure and chronic kidney disease.
- Large body of outcome evidence.
- Multiple potential formulation and method-of-use positions.
- High switching costs in chronic patients.
- Strong brand recognition among cardiologists, nephrologists and endocrinologists.
Weaknesses
- Small-molecule active ingredient is straightforward to manufacture.
- Core compound protection is no longer the principal barrier.
- Generic applicants can challenge secondary patents.
- Diabetes use is vulnerable to therapeutic substitution.
- SGLT2 competition limits the ability to maintain premium pricing.
The patent estate is therefore best characterized as a secondary-protection estate supported by clinical and commercial differentiation, not as an intact composition-of-matter monopoly.
What licensing deals affect dapagliflozin?
Dapagliflozin originated from the collaboration between Bristol-Myers Squibb and AstraZeneca. The companies established a diabetes alliance covering development and commercialization of dapagliflozin and related products. AstraZeneca later became the principal commercial owner of the Farxiga/Forxiga franchise.[7]
Licensing and collaboration economics matter because legacy royalty obligations can affect the product’s net contribution margin. AstraZeneca’s reported product sales are not identical to retained operating profit, especially where collaboration payments, regional rights and distribution arrangements apply.
How much revenue is exposed to dapagliflozin patent expiry?
The direct exposure is AstraZeneca’s annual Farxiga/Forxiga revenue, which reached approximately $5.8 billion in 2023. The broader exposure includes:
- Associated cardiovascular and renal sales infrastructure.
- Clinical-trial investment supporting label expansion.
- Physician relationships in cardiology and nephrology.
- Combination-product opportunities.
- International distributor and payer contracts.
A rapid U.S. generic launch would have a disproportionate effect on profit because branded oral medicines generally have high gross margins. International erosion may arrive earlier in markets where compound patents and secondary patents have expired.
The effect on total AstraZeneca revenue would be material but manageable relative to the company’s diversified oncology, respiratory, immunology and rare-disease portfolio. Farxiga remains more important to growth expectations than to the company’s entire revenue base.
What manufacturing and intellectual-property barriers affect generic dapagliflozin?
Dapagliflozin is a chemically defined small molecule. Generic manufacturers do not face biologic comparability requirements, cold-chain complexity or clinical-trial obligations comparable to biosimilars.
Potential manufacturing barriers include:
- Control of polymorphic or crystalline forms.
- Reproducible tablet dissolution.
- Stability under long-term storage.
- Control of impurities and degradation products.
- Supply of specialized intermediates.
- Regulatory documentation for bioequivalence.
These barriers can delay approval or raise development costs, but they are unlikely to prevent long-term multi-source competition once core patents and enforceable secondary claims no longer block entry.
What is the outlook for the dapagliflozin market?
Dapagliflozin should continue to grow in markets where chronic kidney disease is underdiagnosed and heart-failure treatment rates remain low. Growth will slow as the product matures and as payers compare it with empagliflozin and lower-cost SGLT2 alternatives.
The strongest commercial opportunities are:
- Earlier chronic-kidney-disease detection.
- Use in non-diabetic kidney disease.
- Hospital-to-outpatient heart-failure protocols.
- Broader primary-care prescribing.
- Fixed-dose combinations and adherence programs.
- Emerging-market expansion.
The principal risks are U.S. generic entry, contracting pressure, declining diabetes market share, safety-related prescribing restrictions and competition from empagliflozin and GLP-1 therapies.
Key Takeaways
- Dapagliflozin has become a cardiorenal franchise rather than a diabetes-only product.
- Farxiga/Forxiga sales increased from approximately $2 billion in 2020 to roughly $5.8 billion in 2023.
- Heart failure and chronic kidney disease drive current growth.
- The foundational compound patent is no longer the main U.S. exclusivity barrier.
- Remaining Orange Book patents, formulation claims and method-of-use patents determine generic timing.
- Generic entry is likely to produce staged erosion, with the severity depending on litigation outcomes and settlement terms.
- Empagliflozin is the closest branded competitor.
- GLP-1 therapies are indirect competitors in diabetes and cardiometabolic care.
- Dapagliflozin has no biosimilar risk because it is a small-molecule drug.
- The franchise remains commercially valuable, but its long-term trajectory depends on cardiorenal adoption rather than diabetes volume alone.
FAQs About Dapagliflozin Market and Patent Risk
Is dapagliflozin still a high-growth drug?
Its highest-growth period has likely passed, but heart-failure and chronic-kidney-disease adoption can sustain growth before broad generic entry. The product remains one of AstraZeneca’s major revenue contributors.
Does dapagliflozin have patent protection for chronic kidney disease?
Potential method-of-use and related patents may protect specific uses, but protection depends on the exact patent claims, Orange Book listing and litigation outcome. The active ingredient itself does not receive a new composition-of-matter patent for each indication.
Can generic dapagliflozin be approved for diabetes but not heart failure?
Yes. An ANDA applicant may seek a label carve-out for patented methods of use. The resulting generic label could omit a protected indication if the statutory and regulatory requirements are satisfied.
Is dapagliflozin interchangeable with empagliflozin?
Both are SGLT2 inhibitors, but interchangeability depends on the indication, payer policy, prescriber judgment and applicable regulatory substitution rules. They are not automatically interchangeable in every market.
Will dapagliflozin prices fall after generic launch?
Yes. The magnitude depends on the number of approved suppliers, launch timing, payer formularies, authorized-generic arrangements and whether branded Farxiga retains protected cardiorenal uses.
References
- AstraZeneca PLC. (2024). Annual report and Form 20-F 2023.
- U.S. Food and Drug Administration. (2020). FDA approves new treatment for a type of heart failure.
- U.S. Food and Drug Administration. (2021). FDA approves treatment to reduce risk of declining kidney function in adults with chronic kidney disease.
- U.S. Food and Drug Administration. (2024). Farxiga prescribing information.
- U.S. Patent and Trademark Office. (2003). U.S. Patent No. 6,515,117, C-glucoside derivatives.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- Bristol-Myers Squibb Company & AstraZeneca PLC. (2007). Diabetes collaboration agreement and dapagliflozin development disclosures.
